Inhibikase Therapeutics (IKT) director granted 155,000 options at $1.91 strike

Rhea-AI Filing Summary

Inhibikase Therapeutics, Inc. director Vincent Aurentz received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.9100 per share and expire on June 26, 2036. They vest on the earlier of June 26, 2027 or the day before the next annual stockholder meeting, subject to his continued board service.

Insights

Equity compensation analyst

Director receives routine equity option grant as board compensation.

Director Vincent Aurentz was granted stock options over 155,000 shares of Inhibikase Therapeutics common stock at an exercise price of $1.9100 per share. This is classified as a grant or award acquisition, not an open-market purchase.

The options vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, contingent on continued service. This structure aligns the director’s incentives with long-term performance, while spreading value over the vesting period.

Following this grant, Aurentz holds 155,000 options directly, with expiration on June 26, 2036. Future company filings may detail any additional equity awards or exercises that change his overall equity exposure.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Aurentz Vincent

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	155,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 155,000 shares (Direct)

Footnotes (1)

1. F1. The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Key Figures

Options granted: 155,000 options Exercise price: $1.9100 per share Underlying shares: 155,000 shares +2 more

5 metrics

Options granted 155,000 options Stock Option (Right to Buy) grant to director

Exercise price $1.9100 per share Strike price for granted stock options

Underlying shares 155,000 shares Common stock underlying the options

Expiration date June 26, 2036 Option term to expiration

Vesting date trigger June 26, 2027 Earlier of this date or day before next annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, underlying security, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.9100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-26T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

vesting financial

"The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 04:05 PM Accepted by SEC EDGAR 06/30/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What did Inhibikase Therapeutics (IKT) director Vincent Aurentz receive in this Form 4 filing?

Vincent Aurentz received a grant of stock options for 155,000 shares of Inhibikase Therapeutics common stock. These options are a form of equity compensation, giving him the right to buy shares at a fixed exercise price in the future if conditions are met.

What is the exercise price and expiration date of the IKT options granted to Vincent Aurentz?

The granted stock options have an exercise price of $1.9100 per share and expire on June 26, 2036. This means Aurentz can choose to buy shares at $1.91 up until the expiration date, subject to vesting and other conditions.

How and when do Vincent Aurentz’s Inhibikase Therapeutics options vest?

The options vest on the earlier of June 26, 2027 or the day prior to Inhibikase Therapeutics’ next annual meeting of stockholders. Vesting is conditioned on his continued service as a director through that date, aligning his compensation with ongoing board involvement.

Is the Vincent Aurentz transaction in IKT shares a market buy or sell?

This transaction is an equity grant, not an open-market buy or sell. Aurentz received stock options as compensation, classified as a grant, award, or other acquisition, with no market purchase price paid for the options themselves in this filing.

How many Inhibikase Therapeutics derivative securities does Vincent Aurentz hold after this grant?

After the reported transaction, Aurentz directly holds 155,000 stock options linked to Inhibikase Therapeutics common stock. These options all stem from this grant and remain outstanding through their expiration date, providing potential future ownership if exercised.

What role does Vincent Aurentz hold at Inhibikase Therapeutics related to this option grant?

Vincent Aurentz is identified as a director of Inhibikase Therapeutics in the filing. The option grant functions as board-related equity compensation, with vesting tied to his continued service on the company’s board of directors over the specified period.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aurentz Vincent

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.91	06/26/2026		A		155,000		(1)	06/26/2036	Common Stock	155,000	$0	155,000	D

Explanation of Responses:

1. The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

	/s/ Mark Iwicki, attorney-in-fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)